{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/602b13db8237836e54f27141/6a9ff8990797014d1ec15664?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The New GLP-1 Pills & What You Need to Know","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/602b13db8237836e54f27141/1788868430339-c2166ddd-10c8-4420-8aac-9ada7ec2cc36.jpeg?height=200","description":"<p>Question?</p><p>📢 Ask Dr. Bikman’s Digital Mind (multilingual):</p><p><a href=\"https://benbikman.com/ben-bikmans-digital-ai-mind\" rel=\"noopener noreferrer\" target=\"_blank\">https://benbikman.com/ben-bikmans-digital-ai-mind</a></p><p><br></p><p>📢 Dr. Bikman’s Community &amp; Coaching Site: <a href=\"https://insuliniq.com\" rel=\"noopener noreferrer\" target=\"_blank\">https://insuliniq.com</a></p><p><br></p><p>In today’s mini-lecture, Dr. Ben Bikman explains the new generation of oral GLP-1 medications and why two drugs that come as pills can work very differently. Oral semaglutide is still a peptide, so it requires a special absorption enhancer to protect it from digestion and help it cross the stomach lining. Even then, only about 1% of the dose reaches the bloodstream, requiring strict instructions about taking it on an empty stomach. Orforglipron, by contrast, is a small molecule rather than a peptide, allowing it to survive digestion and be absorbed much more efficiently without the same restrictions.</p><p><br></p><p>Ben reviews studies comparing the drugs for blood glucose control, weight loss, side effects, and maintaining weight loss after injectable GLP-1 therapy. But he emphasizes that changing the delivery method does not change the underlying metabolic rules: insulin still governs whether fat is stored or released.</p><p><br></p><p>Most importantly, Ben argues that GLP-1 medications should be viewed as an opportunity to change metabolic habits rather than simply as long-term weight-loss drugs. Because they can temporarily reduce cravings for sweets and refined carbohydrates, he believes that window should be used to reduce those foods, emphasize protein and fat, and develop habits that can eventually provide an “off-ramp” from the medication..</p><p><br></p><p>References:</p><p>For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&amp;A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: <a href=\"https://www.benbikman.com\" rel=\"noopener noreferrer\" target=\"_blank\">https://www.benbikman.com</a></p><p><br></p><p>NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.</p><p><br></p><p>#GLP1 #GLP1Medications #OralGLP1 #Orforglipron #Semaglutide #WeightLoss #InsulinResistance #Insulin #MetabolicHealth #WeightLossMedication #GLP1WeightLoss #CarbCravings #BloodSugar #Type2Diabetes #Metabolism #LowCarb #DrBenBikman #MetabolicClassroom #MetabolismMatters #HealthScience </p>","author_name":"Insulin IQ"}